Betavert

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Betavert

Quick Facts

Property Description
Active Ingredient Betahistine (as dihydrochloride or hydrochloride)
Form Oral tablets, Oral solution
Pharmacological Class Antivertigo preparation (Histamine analogue)
Common Use Managing dizziness and balance disturbances
Origin Synthetic substance (Aminoalkylpyridine)

Defining Betavert: Identity and Classification

Betavert is a prescription-only pharmaceutical product containing the active substance Betahistine, a synthetic compound classified as an aminoalkylpyridine. This medication is categorized as an antivertigo preparation, specifically designated to manage symptoms associated with vestibular disorders. Betahistine is a unique histamine analogue that acts as both a weak partial H1-receptor agonist and a potent H3-receptor antagonist. This specialized, clinically recognized dual mechanism influences the regulatory systems of the inner ear, distinguishing it from general antihistamines or sedatives.

Composition and General Purpose

Betavert is consistently formulated as a single-ingredient product, containing only Betahistine in a standardized concentration. The medication is primarily available as oral tablets, which is the most common route of administration, though an oral solution may also be offered in specific regions. The overall purpose of Betahistine is to help stabilize inner ear function. Its mechanism is understood to promote blood flow to the cochlear area and facilitate vestibular compensation, which is the brain's ability to adjust to abnormal signals. This action aims to reduce the severity and frequency of sensations related to a profound lack of balance and acute dizziness.

Regulatory References

  1. Betahistine Summary of Product Characteristics (SmPC)

What side effects are possible with Betavert?

Possible Side Effects and Safety Information

Betavert (betahistine) is generally considered well-tolerated, with most adverse reactions being mild. Safety information is derived from regulatory documents, post-marketing surveillance, and clinical data.

Adverse Reactions by Frequency

Classification System-Organ Class Involved Examples of Adverse Reactions
Common (up to 1 in 10) Nervous System, Gastrointestinal Headache, Nausea, Dyspepsia (indigestion)
Rare Immune System, Skin Severe hypersensitivity reaction (e.g., anaphylaxis, rash, pruritus)
Not Known Cardiac, Nervous System, Skin Convulsions, somnolence, confusion, postural hypotension, vomiting, Stevens-Johnson syndrome

The mild gastrointestinal effects, such as nausea or dyspepsia, are often reduced by taking the medication with food.

Safety Restrictions and Monitoring

Contraindications: Betavert is formally contraindicated and must not be used in patients with:

  • A phaeochromocytoma (a tumor of the adrenal gland).
  • An active peptic (stomach) ulcer or a documented history of this condition.

Caution and Monitoring: Special caution and careful monitoring are required for patients with:

  • Bronchial asthma, as the condition may be exacerbated.
  • A history of allergic skin conditions.

Population-Specific Warnings: Use in pediatric patients (under 18) is not recommended due to insufficient data on safety and efficacy in this age group. Similarly, the safety of the drug has not been established in pregnant or breastfeeding women, and its use is typically avoided unless the regulatory authority deems the potential maternal benefit to outweigh the unknown risk to the fetus or infant.

High-Level Safety Note: Patients should be advised that the underlying condition (Ménière's disease) can affect the ability to drive or operate machinery, not the drug itself, which is generally considered to have a negligible effect on these abilities.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documents detail specific manifestations and required actions in the event of Betahistine overdose.


Documented Overdose Manifestations

Overdose presentations are generally categorized into mild-to-moderate effects and serious complications. Common, less severe signs observed may include gastrointestinal disturbances such as nausea, vomiting, dyspepsia, and abdominal pain. Central nervous system effects such as somnolence (drowsiness) and ataxia are also documented.

More severe complications, including convulsions (seizures), pulmonary complications, and cardiac complications, have been associated with high-dose ingestion, particularly in cases of intentional overdose or co-ingestion with other substances.


Emergency Actions and Management

Regulatory authorities mandate that immediate medical attention must be sought for any suspected overdose. This includes contacting a Poison Control Centre or proceeding immediately to a hospital emergency department for timely support.

It is formally stated that no specific antidote is known for Betahistine toxicity. Management involves symptomatic treatment and standard supportive measures. Procedural interventions such as gastric lavage and the administration of activated charcoal are officially recommended.

Therapeutic Uses of Betavert

Quick Facts

  • Primary Focus: Management of Ménière's disease and vestibular disorders.
  • Symptom Relief: Aims to address episodes of vertigo, including the associated spinning sensation.
  • Related Benefits: May assist in reducing the presence of tinnitus and episodes of related hearing changes.

What Betavert Treats: Main Uses and Benefits

Betavert is an oral medication that may be utilized for the supportive management of symptoms related to Ménière's disease. This is an inner ear condition that can present with a combination of difficult-to-manage symptoms.

The medication is indicated for the treatment of recurrent episodes of vertigo, which is characterized by sensations of spinning and dizziness. It may also be used to address other manifestations of the condition, including the perception of ringing or buzzing in the ears (tinnitus) and associated episodes of hearing changes or loss.

For patients diagnosed with vestibular disorders that result in persistent or recurring feelings of imbalance, Betavert may be prescribed to provide symptomatic relief. It is used to help diminish the frequency and severity of these disruptive episodes, supporting overall symptom control and management.

Regulatory References

  1. EMA-affiliated therapeutic summary

Eligibility and Restrictions for Use

Betavert's eligibility for use is strictly defined by regulatory criteria, with use generally established for adult patients (18 years and over) who do not have documented restrictions.

The medicine is contraindicated and must not be used in patients with the following conditions:

  • Pheochromocytoma (a rare adrenal gland tumor).
  • Known hypersensitivity to betahistine or any of the product's excipients.

Age-Group Limitations:

  • Pediatric Patients (Under 18): Use is not recommended due to insufficient data on safety and efficacy in this population.
  • Geriatric Patients (Older Adults): Use is generally permitted.

Conditional and Restricted Use: Close monitoring and caution are required for patients with:

  • Bronchial Asthma or a history of Peptic Ulceration.
  • Hepatic or Renal Impairment, as specific clinical trials for these conditions are absent, and caution is generally advised.

Physiological Status:

  • Pregnancy: Use is not recommended due to limited safety data.
  • Breastfeeding: Use is not recommended, as it is unknown if the medicine is excreted in human milk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Betahistine, the active substance in Betavert, has officially documented interaction patterns primarily concerning its metabolism and pharmacodynamic activity, as stated in regulatory labeling.

Pharmacodynamic and Restricted Combinations

Co-administration with Antihistamines ( H1 antagonists) is restricted due to the theoretical potential for mutual attenuation of therapeutic efficacy. Since Betahistine acts as a histamine analogue, combining it with H1 antagonists may reduce the effectiveness of both drugs.

Metabolic and Exposure-Modifying Interactions

The most significant pharmacokinetic interaction is with Monoamine Oxidase Inhibitors (MAOIs), including MAO-B selective inhibitors (such as Selegiline). Regulatory documents formally advise caution because MAOIs inhibit the metabolism of Betahistine, resulting in increased systemic exposure and reduced clearance of the substance. Betahistine is primarily metabolized by Monoamine Oxidase, and no significant interactions with the Cytochrome P450 enzyme system are expected.

Food and Absorption

Food intake alters the rate of absorption of Betahistine; when taken with food, the drug's maximum plasma concentration ( C max) is lower. However, regulatory data indicates that the total extent of drug absorption ( AUC) is similar regardless of whether the drug is administered with or without a meal. No specific mandatory administration timing rules requiring separation from other medicines are documented in official labeling.

Mechanism of Action

Central Modulation of Vestibular Signal Processing

The action of Betahistine primarily involves its dual influence on the histaminergic system. Centrally, the molecule functions as a Histamine H3 receptor ( H3 R) antagonist in the brain's Vestibular Nuclei ( VN). This blockade removes the presynaptic inhibitory feedback, driving an increase in the synthesis and release of endogenous histamine. The subsequent elevated histamine activity affects neuronal excitability within the VNs and modulates neurotransmitter turnover, leading to a rebalancing of asymmetric signal processing.


Peripheral Action on Labyrinthine Microcirculation

Peripherally, Betahistine also acts as a weak partial Histamine H1 receptor ( H1 R) agonist on the microvasculature of the inner ear. This interaction results in localized vasodilation, which increases perfusion of the cochlear and vestibular labyrinth structures. This augmented perfusion alters the metabolic environment and influences fluid hydrostatic dynamics within the sensory organs. This dual mechanistic pathway combines central regulation with peripheral vascular action, affecting the rate and intensity of vestibular signal transmission.

Dosage and Administration Information

How to Use Betavert: Official Administration Guidelines

Betavert, containing Betahistine as the active substance, is an oral medication administered exclusively via tablets. The total daily dosage is typically between 24 mg and 48 mg, with the maximum recommended daily limit being 48 mg. The available tablet strengths include 8 mg, 16 mg, and 24 mg of betahistine dihydrochloride.


Administration and Scheduling

The total prescribed amount must be administered in 2 or 3 divided doses spread across the day. For example, the maximum daily dose is usually achieved by taking a 24 mg tablet twice daily. This divided use supports consistent exposure to the medicine. The tablets should be taken preferably with or after meals to potentially minimize any mild gastric irritation, and must be swallowed whole with water. Although 16 mg tablets may be divided for precise dose adjustment, the score line on 8 mg tablets is intended only to facilitate swallowing.


Treatment Course and Population Rules

Treatment with Betahistine is often initiated as a long-term course, as an optimal response may only be observed after several weeks or months of continuous use. The prescribed dosage is designed to be individually adjusted based on patient response within established limits.

Regarding specific patient groups, no dose adjustment is generally required for older adults or those with renal or hepatic impairment based on available post-marketing experience. However, Betahistine is not recommended for use in patients under 18 years old due to insufficient data supporting its safety and efficacy in the pediatric population. If a dose is missed, the standard procedure is to skip the missed dose entirely and take the next dose at its regularly scheduled time; a double dose should not be taken.

Recent Clinical Evidence

Research Evidence for Betavert: Overview of Studies

This overview summarizes the available research concerning Betahistine, the active ingredient in Betavert, focusing on the types of clinical evaluations conducted and the outcomes researchers chose to measure. This information is derived from official regulatory sources and peer-reviewed scientific literature.

Evidence for Use in Ménière's Disease

Research exploring how Betahistine relates to the symptoms of Ménière's disease has been a focus of multiple investigations. These include large-scale Randomized Controlled Trials (RCTs) and broad Systematic Reviews that aggregate trial data. Studies primarily included adults with conditions characterized by fluctuating or episodic manifestations of the disease.

The research explored outcomes related to physical discomfort, primarily focusing on the frequency and severity of vertigo attacks and changes in hearing function and tinnitus intensity. The findings were mixed. Some systematic reviews aggregating data described patterns observed in the studies related to symptom reports; however, findings from the largest, highest-quality RCTs did not demonstrate a notable difference compared to placebo on the primary outcome measure (vertigo attack frequency).

Overall, certainty remains low for the evidence base describing this condition. Long-term outcomes related to the disease's overall progression, such as sustained symptom reports or long-lasting reports of symptom control, are not well characterized by high-quality RCT evidence. Due to the highly fluctuating, episodic nature of Ménière's disease itself, it remains a challenge to separate any specific research pattern from the condition's natural variability.


Consistency and Remaining Uncertainties in the Evidence

Scientific reviews consistently highlight that the evidence quality varies across studies concerning Betahistine. Key limitations include inconsistent findings among the most rigorous RCTs and a reliance on pooled data that contains a high risk of bias from methodological shortcomings.

The research gap revolves around the consistency of findings between studies and placebo, the challenge of measuring subjective vertigo symptoms objectively, and the lack of robust, long-term evidence that fully characterizes the medicine's role in the full course of the disease. The evidence contributes to the broader evidence landscape but research does not determine whether an individual will respond similarly.

Frequently Asked Questions (FAQ)

Common questions about Betavert (FAQ)


Q: Can Betavert cause weight gain?

Official regulatory documents list common and rare adverse effects reported during clinical trials and post-marketing use. Weight gain is not typically included as a reported side effect in this official safety information.


Q: Does Betavert affect blood pressure or heart rate?

Regulatory documents describe the need for caution concerning patients who have low blood pressure. Reports of overdose have included instances of accelerated heartbeat (tachycardia) and low blood pressure (hypotension). Regulatory documents also note that postural hypotension (a drop in blood pressure when changing position) has been reported.


Q: Is the drowsiness from Betavert common, and does it usually go away?

Somnolence (drowsiness) is generally listed in regulatory documents as an adverse effect with a frequency of 'Not known,' meaning it is not a common side effect (less than 1 in 10). The official safety information does not specify a typical duration for the effect or whether it commonly resolves if experienced.


Q: Can Betavert cause headaches or migraines?

Headache is listed in regulatory documents as a common side effect of the medicine, which may affect up to 1 in 10 people. However, official information does not specifically define a relationship between taking this medicine and the cause or frequency of migraine attacks.


Q: Is it true that Betavert can help with tinnitus (ringing in the ears)?

The medicine is indicated for managing symptoms of Ménière's syndrome, a condition where tinnitus is a common manifestation. While clinical studies have explored the drug’s potential effect on tinnitus intensity, summaries of the research evidence have presented mixed findings on this specific symptom.


Q: How quickly can I stop taking Betavert once my symptoms improve?

The treatment course for this medicine is often intended to be long-term, as an optimal response may only be seen after weeks or months. Regulatory patient information states that any decision to discontinue the medicine is typically made in consultation with a healthcare professional.


Q: Is it safe to drink alcohol while taking Betavert?

Official regulatory drug labels do not typically list a formal prohibition or a proven hazardous interaction with alcohol. Individuals typically discuss combining medication use with alcohol consumption with a healthcare provider.


Q: Does Betavert interact with antacids or acid-reducing medications?

Official drug labels do not list a specific formal interaction with common antacids. The official product information notes that taking the medication with food may help minimize mild gastrointestinal upset.


Q: Does Betavert have an effect on kidney or liver function?

The medicine is processed in the body and its breakdown product is eliminated primarily via the urine. Regulatory information indicates that caution and monitoring are typically exercised for patients who have existing hepatic (liver) or renal (kidney) impairment.


Q: What are the most serious, but rare, potential side effects of Betavert?

Serious reactions that have been reported during post-marketing use, generally with a frequency of 'Not known' or 'Rare,' include severe hypersensitivity reactions (e.g., anaphylaxis and swelling) and events like convulsions (seizures) reported in cases of very high dose overdose.


Q: How long does a single dose of Betavert last in the body?

Pharmacokinetic data from regulatory sources show that the active substance is rapidly processed by the body. Its main derivative typically reaches maximum levels in the blood around 1 hour after intake and declines with a half-life of approximately 3.5 hours.


Q: Why does the packaging of Betavert sometimes mention a risk of allergic reactions?

The packaging mentions this risk because severe hypersensitivity reactions (allergic reactions), including anaphylaxis (a serious, life-threatening allergic reaction) and severe skin reactions, have been reported in post-marketing surveillance for the active substance.


Q: Is there a generic version of Betavert available?

Regulatory databases list numerous products containing the active ingredient Betahistine that are authorized by various agencies globally. This indicates that the active ingredient is available under multiple brand names and generic listings in different regions.


Q: Can Betavert be taken with other medications for anxiety or sleep?

Official drug labels specifically warn about potential interactions with certain drugs, such as Antihistamines and MAO inhibitors. No specific formal contraindications are generally listed for common medications used for anxiety or sleep, such as SSRIs or benzodiazepines.


Q: Will Betavert prevent future vertigo episodes?

The medicine is prescribed for the long-term management of symptoms associated with the condition. Regulatory summaries note that robust, high-quality evidence does not consistently demonstrate a notable difference compared to placebo on the primary measure of vertigo attack frequency.


Q: Does Betavert make you dizzy when you first start taking it?

Dizziness and vertigo are primary symptoms of the condition being treated, not generally listed as a common direct side effect of the medicine itself. According to official documents, the drug is considered to have no or negligible effects on the ability to drive or use machines.


Q: What is the evidence level for Betavert in treating non-Meniere's vertigo?

The medicine is primarily indicated for the treatment of Ménière's syndrome. While healthcare providers may sometimes use it for other causes of vertigo, regulatory documents generally restrict the official, authorized indication to conditions that fall within the scope of symptoms for Ménière's disease.

How should Betavert be stored and disposed of?

The official regulatory labeling for Betahistine (Betavert) tablets specifies clear conditions for storage and disposal to ensure product stability and safety.

Storage and Handling Requirements

Requirement Area Official Regulatory Constraint
Temperature Store at a temperature not exceeding 30 C or according to the labeled room temperature [Source 1.2, 1.4].
Protection Store in the original pack in order to protect from moisture [Source 1.6].
Child Safety Keep out of the sight and reach of children [Source 1.5].

Disposal Instructions

Official labeling for the finished product often states No special requirements for disposal [Source 1.2, 2.1]. However, medicine should not be disposed of via wastewater or household waste. Unused or expired medication must be discarded according to local regulations [Source 3.2].

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Betavert found in:

A-Z Index: